share_log

TherapeuticsMD Analyst Ratings

TherapeuticsMD Analyst Ratings

TherapeuticsMD 分析師評
Benzinga ·  2023/08/17 11:47
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/17/2023 39.66% Cantor Fitzgerald → $5 Reiterates Neutral → Neutral
01/11/2023 39.66% Cantor Fitzgerald → $5 Reinstates → Neutral
07/13/2022 -72.07% Cantor Fitzgerald → $1 Reiterates → Neutral
06/07/2022 179.33% HC Wainwright & Co. → $10 Downgrades Buy → Neutral
05/06/2022 -72.07% Cantor Fitzgerald $5 → $1 Downgrades Overweight → Neutral
03/11/2022 -30.17% HC Wainwright & Co. $3 → $2.5 Maintains Buy
11/12/2021 -16.2% HC Wainwright & Co. $4 → $3 Maintains Buy
08/07/2020 -66.48% Jefferies $1.25 → $1.2 Downgrades Hold → Underperform
05/19/2020 — JP Morgan Downgrades Overweight → Neutral
05/07/2020 39.66% HC Wainwright & Co. $6 → $5 Reiterates → Buy
04/16/2020 318.99% Stifel $14 → $15 Maintains Buy
02/21/2020 67.6% HC Wainwright & Co. $7 → $6 Maintains Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年08月17日 39.66% 康託·菲茨傑拉德 →$5 重申 中性→中性
2023年1月11日 39.66% 康託·菲茨傑拉德 →$5 恢復 →中性
07/13/2022 -72.07% 康託·菲茨傑拉德 →$1 重申 →中性
06/07/2022 179.33% HC Wainwright公司 →$10 評級下調 購買→中性
05/06/2022 -72.07% 康託·菲茨傑拉德 $5→$1 評級下調 超重→中性
03/11/2022 -30.17% HC Wainwright公司 $3→$2.5 維護 買
2021年11月12日 -16.2% HC Wainwright公司 $4→$3 維護 買
08/07/2020 -66.48% 傑富瑞 $1.25→$1.2 評級下調 持有→表現不佳
2020/05/19 - 摩根大通 評級下調 超重→中性
05/07/2020 39.66% HC Wainwright公司 $6→$5 重申 →購買
04/16/2020 318.99% Stifel $14→$15 維護 買
02/21/2020 67.6% HC Wainwright公司 $7→$6 維護 買

What is the target price for TherapeuticsMD (TXMD)?

TreateuticsMD(TXMD)的目標價格是多少？

The latest price target for TherapeuticsMD (NASDAQ: TXMD) was reported by Cantor Fitzgerald on August 17, 2023. The analyst firm set a price target for $5.00 expecting TXMD to rise to within 12 months (a possible 39.66% upside). 2 analyst firms have reported ratings in the last year.

康託·菲茨傑拉德於2023年8月17日報道了TreateuticsMD(納斯達克：TXMD)的最新目標價。這家分析公司將目標價定為5.00美元，預計TXMD將在12個月內升至(可能上漲39.66%)。去年有兩家分析公司公佈了評級。

What is the most recent analyst rating for TherapeuticsMD (TXMD)?

最近分析師對TreateuticsMD(TXMD)的評級是多少？

The latest analyst rating for TherapeuticsMD (NASDAQ: TXMD) was provided by Cantor Fitzgerald, and TherapeuticsMD reiterated their neutral rating.

TreateuticsMD(納斯達克代碼：TXMD)的最新分析師評級是由坎託·菲茨傑拉德提供的，TreateuticsMD重申了他們的中性評級。

When is the next analyst rating going to be posted or updated for TherapeuticsMD (TXMD)?

下一次分析師對TreateuticsMD(TXMD)的評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TherapeuticsMD, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TherapeuticsMD was filed on August 17, 2023 so you should expect the next rating to be made available sometime around August 17, 2024.

分析師在進行了廣泛的研究後得出股票評級，其中包括查看公共財務報表，與TreeuticsMD的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。TreeuticsMD的上一次評級是在2023年8月17日提交的，所以你應該預計下一次評級將在2024年8月17日左右提供。

Is the Analyst Rating TherapeuticsMD (TXMD) correct?

分析師對TreeuticsMD(TXMD)的評級正確嗎？

While ratings are subjective and will change, the latest TherapeuticsMD (TXMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price TherapeuticsMD (TXMD) is trading at is $3.58, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的治療MD(TXMD)評級被重申，目標價在0.00美元到5.00美元之間。TreateuticsMD(TXMD)目前的交易價格為3.58美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論